MAFLD – Fibronostics

LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patients

easlfibronostg on June 29, 2026

LIVERFASt identifies advanced (F3F4) and clinically significant fibrosis (F2-F4) especially well with Fibroscan in MASLD patients

easlfibronostg on June 29, 2026

LIVERSTAT first-line screening tool: MAFLD patients outperformed standard-of-care FIB-4 (training/validation)

easlfibronostg on June 29, 2026

LIVERSTAT as NIT for risk stratification for MAFLD — a single-centre study using liver biopsy as reference standard (Malaysia)

easlfibronostg on June 26, 2026

Long-term prognosis of MAFLD patients according to non-invasive methods